GlassScriptPhysician profile
Diego Mastronardi
NPI 1104822626
$8,424.09
in general payments reported to CMS, 2019-2025
45 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $502 · 2021: $1,160 · 2022: $1,187 · 2023: $1,335 · 2024: $1,169 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.44 |
| Education | $153.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,210.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,117.89 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Novo Nordisk INC | $980.26 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $883.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $819.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $654.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $337.26 | 2019-2025 | Arexvy, Shingrix, Nucala |
| Radius Health, INC. | $283.98 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $264.91 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $247.65 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.42 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $204.84 | 2022 | |
| Amarin Pharma, INC. | $138.08 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.99 | 2021-2025 | |
| Lundbeck LLC | $111.63 | 2021-2025 | Vyepti |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Mastronardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.